Sana Biotechnology (NASDAQ:SANA) Announces Earnings Results, Beats Expectations By $0.02 EPS

Sana Biotechnology (NASDAQ:SANA) released its earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02, FiscalAI reports.

Sana Biotechnology Price Performance

NASDAQ SANA opened at $3.79 on Wednesday. Sana Biotechnology has a 1-year low of $2.61 and a 1-year high of $6.55. The firm has a market capitalization of $1.05 billion, a P/E ratio of -4.99 and a beta of 2.16. The business’s 50-day simple moving average is $3.32 and its 200-day simple moving average is $3.47.

Institutional Trading of Sana Biotechnology

Large investors have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV acquired a new position in Sana Biotechnology during the 3rd quarter worth approximately $36,000. Russell Investments Group Ltd. bought a new position in shares of Sana Biotechnology during the third quarter worth about $39,000. Jacobi Capital Management LLC bought a new position in shares of Sana Biotechnology during the fourth quarter worth about $41,000. BNP Paribas Financial Markets increased its holdings in shares of Sana Biotechnology by 46.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock worth $42,000 after acquiring an additional 4,931 shares during the period. Finally, Captrust Financial Advisors lifted its position in Sana Biotechnology by 43.8% in the 2nd quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock valued at $43,000 after purchasing an additional 4,807 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SANA shares. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Weiss Ratings raised shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a report on Monday, May 11th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Wedbush boosted their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Sana Biotechnology has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.